[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-depressive-disorder-with-excessive-daytime-sleepiness-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-depressive-disorder-with-excessive-daytime-sleepiness-symptoms":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100630172","phase-3-clinical-assessment-of-response-in-the-treatment-of-depression-with-daytime-sleepiness-using-solriamfetol-100630172",false,"NCT07484217","Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol","A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms","CLARITY","Inclusion Criteria:\n\n* Currently meets the DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT\n* Excessive daytime sleepiness symptoms\n* Able to comply with study procedures\n* Male or female, aged 18 to 65 years inclusive\n\nExclusion Criteria:\n\n* Any clinically significant medical (e.g., OSA, narcolepsy), behavioral, or psychiatric disorder, other than MDD with EDS symptoms\n* Unable to comply with study procedures\n* Medically inappropriate for study participation in the opinion of the investigator","ALL","18 Years","65 Years",{"count":21,"type":22},508,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.",[28],"Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms",[30,31,32,33,34,35,36,37,38,39,40],"Solriamfetol","Sunosi","Major Depressive Disorder with excessive daytime sleepiness","Major Depressive Disorder","MDD","Axsome","Non-stimulant therapy","Dopamine norepinephrine reuptake inhibitor","Trace amine-associated receptor 1 (TAAR1) agonist","Excessive daytime sleepiness","EDS","RECRUITING","2026-03-16",{"date":44,"type":45},"2026-03-20","ACTUAL",{"date":47,"type":45},"2026-02-23",{"date":49,"type":22},"2028-12",{"name":51,"class":52},"Axsome Therapeutics, Inc.","INDUSTRY",13]